Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Lulea – page 2

31 clinical trials in Lulea, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Lulea at a glance
31
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

31 trials in Lulea

Open in trial search

Non-small cell lung cancer

Not recruiting

Study on Durvalumab and Stereotactic Body Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vaestra Goetalandsregionen

Type 2 diabetes mellitus

Not recruiting

Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol
  • Sponsor:Uppsala University

Mantle cell lymphoma

Not recruiting

Study of Acalabrutinib and Rituximab for Elderly Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Polycythaemia vera+10

Not recruiting

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Panobinostat
  • Sponsor:Novartis Pharma Services AG

Mantle cell lymphoma

Not recruiting

Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088
  • Sponsor:Bayer AG

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Hypercholesterolaemia

Not recruiting

Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Lulea

What the registry says about research in the country

01 Hematologic Oncology

Extensive research in Stockholm focusing on chronic lymphocytic leukemia (CLL) and various blood cancers, testing novel therapeutic combinations and treatment approaches.

  • Multiple Myeloma Treatment Studies
  • Leukemia Therapy Innovations
  • Lymphoma Management Strategies

Several trials evaluating combination therapies with drugs like ibrutinib, venetoclax, and rituximab for improved patient outcomes.

02 Preventive Medicine

Studies focused on prevention and early intervention, including a groundbreaking trial combining HPV vaccination and screening for cervical cancer elimination.

  • Cancer Prevention Protocols
  • Vaccination Strategies
  • Population Health Initiatives

Research aimed at developing more effective disease prevention strategies and improving public health outcomes.

03 Solid Tumor Research

Innovative studies examining treatments for non-small cell lung cancer and colorectal cancer, with focus on targeted therapies and personalized medicine approaches.

  • Targeted Cancer Therapies
  • Mutation-Specific Treatments
  • Immunotherapy Applications

Trials investigating novel therapeutic approaches for patients with specific genetic mutations and biomarkers.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.